Kymera Investor Presentation Deck
Up to 88% Mean Maximum Nearing Desired Degradation Profile at
DL3 as of May 1, 2023 (ICML)
-20
-40
DL2
wall
DL3
Cycle 2 weeks 1 & 2
T T
T
8 9 10 11 12 29 30 31 32 33 34 35 36 37 38
-60
-80
-100
KT-333
●
●
●
Time course of STAT3 degradation
Method: Targeted Mass Spectrometry
1
Cycle 1 weeks 1 & 2
T T
2
T
3 4 5 6 7
Days in Study
Maximum Degradation across individual patients
Cycle 2
(D29-D37)
DL1
KYMERA ©2023 KYMERA THERAPEUTICS, INC.
-50
-60
-70
-80
-90
-100
DL1
Cycle 1
(D1-D12)
DL2
●
1
• 1
DL3 DL2
DL3
Values below LLOQ
Dose-dependent STAT3 degradation
Mean maximum degradation of up to 85.4% in Cycle 1 and 88.4% in Cycle 2
Weekly maximum reductions of up to 90-91%
Profile at or nearing STAT3 degradation shown to lead to strong antitumor effects in preclinical models
As of the data cut-off date of May 1, 2023.
PAGE 27View entire presentation